The incidence of melanoma is increasing and prolonged exposure to ultraviolet (UV)
radiation remains the main risk factor. Public health measures have been vital in tackling the …

Incidence of malignant melanoma has been increasing since the 1980s. For loco-regional
stages, surgery is still the best treatment. Melanoma has a high distant metastatic potential …

Metastatic melanoma has a poor prognosis and until recently systemic therapy was
ineffective. Advances in the understanding of tumour biology and immune regulation have …

Outcomes for patients with melanoma have improved over the past decade with the clinical
development and approval of immunotherapies targeting immune checkpoint receptors such …

The treatment landscape of advanced melanoma has changed significantly following the
discovery and marketing authorisation of immune checkpoints inhibitors. Ipilimumab (anti …

The prognosis for patients with stage IV melanoma has historically been extremely poor and
there have until recently been no effective treatment options. The last 3 years have seen a …

Background The systemic treatment of metastatic melanoma has improved considerably
with the introduction of new, targeted substances and immune checkpoint inhibitors. This …

Immunotherapy with immune-checkpoint inhibitors and molecularly targeted therapy with
BRAF inhibitors were pioneered in the setting of advanced-stage, unresectable melanoma …

Melanoma is the most fatal skin cancer. In the early stages, it can be safely treated with
surgery alone. However, since 2011, there has been an important revolution in the treatment …

The incidence of melanoma in both males and females continues to rise during the past 40
years despite the stable or declining trends for most cancer types. Due to the tremendous …